Sorafenib treatment and safety profile in Child Pugh B patients characterized in first interim results of GIDEON (global investigation of therapeutic decisions in hepatocellular c…

Introduction: The aim of GIDEON, the largest ongoing, global, prospective, non-interventional study of patients (pts) with unresectable HCC (uHCC) eligible for systemic therapy and receiving sorafenib (Sor), is to evaluate Sor safety and efficacy in diverse real-life clinical settings and pt subgroups where data are limited, eg, Child Pugh B. Methods: Demographic data, medical, disease and treatment history are recorded. At follow-up visits Sor dose, concomitant treatments, performance status, liver function, adverse events (AEs) and efficacy, assessed according to Response Evaluation Criteria in Solid Tumors, a…